Metformin mitigates stress-induced premature senescence by upregulating AMPKα at Ser485 phosphorylation induced SIRT3 expression and inactivating mitochondrial oxidants. (September 2022)

• Record Type: Journal Article
• Authors: Sung, Jin Young; Kim, Seul Gi; Kang, Young Jin; Choi, Hyoung Chul
• Is Part Of: Mechanisms of ageing and development. Volume 206(2022)
• Publication Date: 2022-09
• Subjects: Metformin -- VSMC senescence -- Mitochondrial ROS -- P-AMPK (Ser485) -- SIRT3 -- SOD2 acetylation; Aging -- Periodicals; Developmental biology -- Periodicals; Aging -- Periodicals; Developmental Biology -- Periodicals; Vieillissement -- Périodiques; Biologie du développement -- Périodiques; Aging; Developmental biology; Periodicals; 612.67
• DOI: 10.1016/j.mad.2022.111708
• Languages: English
• ISSNs: 0047-6374

Abstract

Abstract: The senescence of vascular smooth muscle cells (VSMCs) is an important cause of cardiovascular disease such as atherosclerosis and hypertension. These senescence may be triggered by many factors, such as oxidative stress, inflammation, DNA damage, and senescence-associated secretory phenotypes (SASPs). Mitochondrial oxidative stress induces cellular senescence, but the mechanisms by which mitochondrial reactive oxygen species (mtROS) regulates cellular senescence are still largely unknown. Here, we investigated the mechanism responsible for the anti-aging effect of metformin by examining links between VSMC senescence and mtROS in in vitro and in vivo. Metformin was found to increase p-AMPK (Ser485), but to decrease senescence-associated phenotypes and protein levels of senescence markers during ADR-induced VSMC senescence. Importantly, metformin decreased mtROS by inducing the deacetylation of superoxide dismutase 2 (SOD2) by increasing SIRT3 expression. Moreover, AMPK depletion reduced the expression of SIRT3 and increased the expression of acetylated SOD2 despite metformin treatment, suggesting AMPK activation by metformin is required to protect against mitochondrial oxidative stress by SIRT3. This study provides mechanistic evidence that metformin acts as an anti-aging agent and alleviates VSMC senescence by upregulating mitochondrial antioxidant induced p-AMPK (Ser485)-dependent SIRT3 expression, which suggests metformin has therapeutic potential for the treatment of age-associated vascular disease. Highlights: Metformin induces expression of p-AMPK (Ser485) in ADR-induced senescent VSMCs. AMPK (Ser485) phosphorylation by metformin upregulates the expression of SIRT3. Metformin decreased mtROS by inducing the deacetylation of superoxide dismutase 2 by increasing SIRT3 expression. AMPK depletion reduced the expression of SIRT3 and increased the expression of acetylated SOD2 despite metformin treatment. Metformin exhibits anti-aging effects in ADR-injected mice via p-AMPK (Ser485) - SIRT3 - decreased mitochondrial ROS pathway.